Cornerstone Biosciences

CStone Pharmaceuticals is a leading biopharmaceutical company focused on the discovery, development, and commercialization of innovative immuno-oncology and precision medicines. Founded in 2015 and headquartered in Suzhou, China, the company was originally known as Cornerstone Biosciences and continues to operate its primary R&D through its Cornerstone Biosciences (Suzhou) subsidiary. CStone has established a robust pipeline of over 15 oncology assets, including several that have received regulatory approval in Greater China, such as the PD-L1 inhibitor sugemalimab and the RET inhibitor pralsetinib. The company utilizes a dual-source innovation model, combining internal R&D with strategic global partnerships with firms like Pfizer, Blueprint Medicines, and Servier. CStone is publicly traded on the Hong Kong Stock Exchange and is actively expanding its portfolio into next-generation modalities like antibody-drug conjugates and bispecific antibodies.